Two Sigma Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-19,700
Closed -$833K 3429
2024
Q1
$833K Hold
19,700
﹤0.01% 2065
2023
Q4
$835K Sell
19,700
-4,300
-18% -$124K ﹤0.01% 2179
2023
Q3
$524K Sell
24,000
-8,300
-26% -$208K ﹤0.01% 2254
2023
Q2
$1.03M Buy
32,300
+18,600
+136% +$571K ﹤0.01% 1931
2023
Q1
$334K Buy
13,700
+5,700
+71% +$167K ﹤0.01% 2374
2022
Q4
$252K Buy
+8,000
New +$226K ﹤0.01% 2309

Other funds holding CERE

Two Sigma Investments's CERE Position: Q2 2024 in Review

Two Sigma Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 19,700 shares — an estimated $833K sold.

Two Sigma Investments first reported a position in CERE in Q4 2022 and held it in 6 quarters. The position peaked at $1.03M in Q2 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Two Sigma Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Investments sold 19,700 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $833K.
  • Two Sigma Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
  • Two Sigma Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.03M in Q2 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.